Olmsted Medical Center-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Olmsted Medical Center - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013353
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Olmsted Medical Center (OMC) is a healthcare service provider that offers patient care and clinical research services. The center offers services in the areas of general surgery, podiatry, pain management, dermatology, plastic surgery, inpatient dietary services, pediatrics, diabetes education, neurology, psychiatry, psychology, nutrition education and weight loss surgery, among others. It also offers birth center, laboratory services, radiology, diagnostic imaging, rheumatology, endocrinology, rehabilitation services, ENT, respiratory therapy, emergency medicine, audiology, anticoagulation clinic and others. The center offers services through collaboration with psychology and psychiatry, nutrition education, and surgery caregivers. It operates in Chatfield, St Charles, Cannon Falls, Byron, Preston, Spring Valley and other cities of Minnesota. OMC is headquartered in Rochester, Minnesota, the US.

Olmsted Medical Center – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Olmsted Medical Center, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deal Details 9
Debt Offering 9
Olmsted Completes Public Offering Of Series 2010 Bonds Due 2020 For US$4.2 Million 9
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2015 For US$0.5 Million 10
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2016 For US$0.63 Million 11
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2017 For US$0.65 Million 12
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2018 For US$0.68 Million 13
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2019 For US$0.71 Million 14
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2020 For US$0.75 Million 15
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2021 For US$0.79 Million 16
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2022 For US$0.83 Million 17
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2023 For US$0.87 Million 18
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2024 For US$0.9 Million 19
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2025 For US$0.9 Million 20
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2026 For US$0.96 Million 21
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2027 For US$0.99 Million 22
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2028 For US$1.04 Million 23
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2029 For US$1.1 Million 24
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2033 For US$4.9 Million 25
Olmsted Medical Center – Key Competitors 26
Olmsted Medical Center – Key Employees 27
Olmsted Medical Center – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Olmsted Medical Center, Pharmaceuticals & Healthcare, Key Facts 2
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Olmsted Medical Center, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Olmsted Completes Public Offering Of Series 2010 Bonds Due 2020 For US$4.2 Million 9
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2015 For US$0.5 Million 10
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2016 For US$0.63 Million 11
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2017 For US$0.65 Million 12
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2018 For US$0.68 Million 13
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2019 For US$0.71 Million 14
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2020 For US$0.75 Million 15
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2021 For US$0.79 Million 16
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2022 For US$0.83 Million 17
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2023 For US$0.87 Million 18
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2024 For US$0.9 Million 19
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2025 For US$0.9 Million 20
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2026 For US$0.96 Million 21
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2027 For US$0.99 Million 22
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2028 For US$1.04 Million 23
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2029 For US$1.1 Million 24
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2033 For US$4.9 Million 25
Olmsted Medical Center, Key Competitors 26
Olmsted Medical Center, Key Employees 27
Olmsted Medical Center, Other Locations 28
Olmsted Medical Center, Subsidiaries 29

★海外企業調査レポート[Olmsted Medical Center-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Immune Pharmaceuticals Inc (IMNP):企業の財務・戦略的SWOT分析
    Summary Immune Pharmaceuticals Inc (Immune Pharma), formerly EpiCept Corp is a drug development company that develops novel therapies for immunologic and inflammatory diseases. The company’s pipeline products include Bertilimumab and Nanocyclo. Its Bertilimumab is a human monoclonal antibody designe …
  • KUKA AG (KU2):企業の財務・戦略的SWOT分析
    KUKA AG (KU2) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Oil and Natural Gas Corporation Limited:企業の戦略・SWOT・財務分析
    Oil and Natural Gas Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Oil and Natural Gas Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Zhejiang Xianju Pharmaceutical Co Ltd (002332):製薬・医療:M&Aディール及び事業提携情報
    Summary Zhejiang Xianju Pharmaceutical Co Ltd (Zhejiang Xianju Pharmaceutical) is a contract manufacturer of API and formulations. The company offers products such as ingredients, active pharmaceutical ingredients, steroids and hormones, pharmaceutical products, and finished formulations, among othe …
  • PT Garuda Indonesia (Persero) Tbk:企業の戦略・SWOT・財務情報
    PT Garuda Indonesia (Persero) Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Garuda Indonesia (Persero) Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Travelport Limited (TVPT):企業の財務・戦略的SWOT分析
    Travelport Limited (TVPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • CSE Global Limited (544):企業の財務・戦略的SWOT分析
    CSE Global Limited (544) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Safaricom Ltd
    Safaricom Ltd - Strategy, SWOT and Corporate Finance Report Summary Safaricom Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Ventana Medical Systems Inc-製薬・医療分野:企業M&A・提携分析
    Summary Ventana Medical Systems Inc (VMS), a subsidiary of F. Hoffmann-La Roche Ltd is a manufacturer of tissue-based diagnostic solutions for healthcare market. The company develops cancer diagnostic solutions for breast pathology, cervical diagnostics, colorectal pathology, special stains, lung pa …
  • Hitachi Capital (UK) PLC:企業の戦略・SWOT・財務情報
    Hitachi Capital (UK) PLC - Strategy, SWOT and Corporate Finance Report Summary Hitachi Capital (UK) PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • L’Oreal USA Inc:企業の戦略的SWOT分析
    L'Oreal USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Quickstep Holdings Limited:企業の戦略・SWOT・財務情報
    Quickstep Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Quickstep Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Univision Communications Inc.:企業の戦略・SWOT・財務分析
    Univision Communications Inc. - Strategy, SWOT and Corporate Finance Report Summary Univision Communications Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • PIQUR Therapeutics AG-製薬・医療分野:企業M&A・提携分析
    Summary PIQUR Therapeutics AG (PIQUR) is a clinical-stage pharmaceutical company that discovers and develops anti-cancer drugs. The company develops innovative small molecule therapeutics based on lipid kinase (PI3K) and mTOR inhibitior for the treatment of cancer and inflammatory diseases. Its pipe …
  • The Walt Disney Company:戦略・SWOT・企業財務分析
    The Walt Disney Company - Strategy, SWOT and Corporate Finance Report Summary The Walt Disney Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Wallenstam AB (WALL B):企業の財務・戦略的SWOT分析
    Summary Wallenstam AB (Wallenstam) is a construction company that offers building and property management solutions. The company's services include commercial and residential properties development, housing programs, property investment and management, urban development, property ownership services, …
  • Kaiser Foundation Health Plan of Washington:企業の戦略的SWOT分析
    Kaiser Foundation Health Plan of Washington - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • Korea Electric Power Corporation (015760):企業の財務・戦略的SWOT分析
    Korea Electric Power Corporation (015760) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Gunsynd Plc (GUN):企業の財務・戦略的SWOT分析
    Gunsynd Plc (GUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Daniel Thwaites Plc:戦略・SWOT・企業財務分析
    Daniel Thwaites Plc - Strategy, SWOT and Corporate Finance Report Summary Daniel Thwaites Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆